Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the
safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of
BCX10013 in participants with paroxysmal nocturnal hemoglobinuria (PNH). Approximately 15
participants will be enrolled in this study. Participants may receive treatment for up to 24
weeks.